IL1B and coronary artery disorder: As the IL-1 pathway is a promising target for anti-inflammatory therapy, other antibodies are being developed such as anakinra, an antibody inhibiting IL-1 receptor, that has shown promising results in phase II clinical trials in both stable (47) and unstable patients (48) at high CV risk, reflecting the importance of targeting inflammation during both the acute and chronic phases of coronary artery disease (CAD).